The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
JACC: Advances · 2023-11 · 2 (9) · 100648
DOI: 10.1016/j.jacadv.2023.100648 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Advances, 2023-11. Verfasst von Frederick J Raal und 15 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc.
Abstract (Originalsprache)
Background
Homozygous familial hypercholesterolemia (HoFH) is characterized by early-onset atherosclerotic cardiovascular disease due to the high low-density lipoprotein cholesterol (LDL-C) burden. Patients with null-null low-density lipoprotein receptor (LDLR) variants respond poorly, if at all, to statins and proprotein convertase subtilisin/kexin type 9 inhibitors, which act by upregulating LDLR expression. The 24-week double-blind treatment period (DBTP) of the phase 3 ELIPSE HoFH (Evinacumab Lipid Studies in Patients with Homozygous Familial hypercholesterolemia; NCT03399786) study demonstrated significant LDL-C reductions in patients with HoFH; LDL-C reductions were also observed in those with null-null LDLR mutations.
Objectives
The purpose of this study was to evaluate longer-term efficacy and safety of evinacumab in patients with HoFH from the ELIPSE HoFH study.
Methods
Patients with HoFH on stable lipid-lowering therapies (LLTs) ± lipoprotein apheresis and screening LDL-C ≥70 mg/dL who completed the DBTP entered the 24-week open-label treatment period (OLTP) and received intravenous evinacumab 15 mg/kg every 4 weeks. OLTP results were summarized descriptively.
Results
A total of 64 patients completed the DBTP and received open-label evinacumab. Despite multiple LLTs, the mean baseline LDL-C at DBTP entry was 250.5 ± 162.3 mg/dL. From baseline to week 48 (end of OLTP), evinacumab reduced mean LDL-C by 46.3% (mean reduction, 134.3 ± 117.3 mg/dL), with similar mean LDL-C reductions for patients with null-null (47.2%) and non-null variants (45.9%). Adverse events occurred in 47 (73.4%) patients; 4 (6.3%) patients experienced adverse events considered evinacumab-related (drug hypersensitivity, infusion-related reaction and asthenia, generalized pruritis, and muscle spasms).
Conclusions
In patients with HoFH, evinacumab demonstrated substantial and sustained LDL-C reduction regardless of LDLR function, and was generally well tolerated.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Cardiometabolics Unit, Zena and Michael A Wiener Cardiovascular Institute, Marie-Josee and Henry R. Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Internal Medicine and Surgery, Federico II University, Naples, Italy.
- Knight Cardiovascular Institute and Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, Oregon, USA.
- Division of Cardiovascular Medicine, Department of Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Förderung
- Regeneron Pharmaceuticals Inc
Zitieren
APA
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Kastelein, J. J. P., Rubba, P., Duell, P. B., Koseki, M., Stroes, E., Ali, S., Banerjee, P., Chan, K. C., Khilla, N., McGinniss, J., Pordy, R., Zhang, Y., & Gaudet, D. (2023). The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia. JACC: Advances, 2(9), 100648. https://doi.org/10.1016/j.jacadv.2023.100648
Vancouver
Raal FJ, Rosenson RS, Reeskamp LF, Kastelein JJP, Rubba P, Duell PB, et al. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia. JACC: Advances. 2023;2(9):100648. doi:10.1016/j.jacadv.2023.100648
BibTeX
@article{Raal2023,
author = {Raal, Frederick J and Rosenson, Robert S and Reeskamp, Laurens F and Kastelein, John J P and Rubba, Paolo and Duell, P Barton and Koseki, Masahiro and Stroes, Erik and Ali, Shazia and Banerjee, Poulabi and Chan, Kuo-Chen and Khilla, Nagwa and McGinniss, Jennifer and Pordy, Robert and Zhang, Yi and Gaudet, Daniel},
title = {The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia},
journal = {JACC: Advances},
year = {2023},
volume = {2},
number = {9},
pages = {100648},
doi = {10.1016/j.jacadv.2023.100648}
}
EUVIMED